Advisers say FDA's opioid REMS program needs improvement

Am J Health Syst Pharm. 2016 Jul 1;73(13):940-2. doi: 10.2146/news160040.
No abstract available

Publication types

  • News

MeSH terms

  • Advisory Committees / standards*
  • Analgesics, Opioid* / administration & dosage
  • Analgesics, Opioid* / adverse effects
  • Delayed-Action Preparations / administration & dosage
  • Delayed-Action Preparations / adverse effects
  • Humans
  • Risk Assessment
  • Risk Factors
  • United States
  • United States Food and Drug Administration / standards*

Substances

  • Analgesics, Opioid
  • Delayed-Action Preparations